Skip to main content

Yubo International Biotech Ltd

corporate_fare Company Profile

Yubo International Biotech Ltd

YBGJ·OTC·Industrial Applications And Services·CIK 0000895464

The company is a U.S. holding company that primarily operates through its wholly owned subsidiary, Platinum International Biotech Co., Ltd., a Cayman Islands company. Platinum, also a holding company, operates in China through its subsidiaries and contractual arrangements with a variable interest entity (VIE), Yubo International Biotech (Beijing) Limited ("Yubo Beijing"). Neither the U.S. holding company, Platinum, nor Platinum International Biotech (Hong Kong) Limited (a wholly owned subsidiary of Platinum) conducts day-to-day business operations in China. Yubo Beijing, a technology company based in China, conducts the day-to-day business operations through contractual arrangements with the company's subsidiaries. Yubo Beijing focuses on the research, development, and application of endometrial stem cells and aims to build the world's first public endometrial stem cell repository. Yubo Beijing offers products and services under the "VIVCELL" brand. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. Yubo Beijing also provides stem cell-related services, including cell testing and health management consulting services. The company's corporate structure, involving the VIE, provides contractual exposure to foreign investment in China-based companies in industries where direct foreign investment is prohibited by PRC laws, such as Yubo Beijing. Investors in the company's Class A common stock do not hold, and may never hold, any direct or indirect equity interest in Yubo Beijing or its subsidiaries.

Yubo International Biotech Ltd (OTC:YBGJ) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors YBGJ SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Yubo Biotech Confirms Board, Auditor Amid Going Concern Warning
  • Yubo Biotech Q1 Revenue Falls 6.8% to $191.79K; Net Loss Narrows to $295.03K Amid Paused Product Sales
  • Yubo International Biotech Reports Zero Revenue, Going Concern Warning, and Increased Reliance on Related Party Loans

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$12.35K
Net Income
-$1.08M
Diluted EPS
-$0.01
Op. Cash Flow
-$842.8K
Gross Profit
$8.16K
Operating Income
-$1.19M
Cash & Equivalents
$8.06K
Debt / Equity
0.00×
Net Margin
-87.37×
Source: 10-K · filed 2026-03-31 · accession 0001640334-26-000598
Browse all tickers starting with Y →
$0.0071
52-week range · as of 2026-06-12 $0.0079 – $1.37
Market cap
$1.21M
Volume
228 (0.0× avg)
3-mo avg 108.1K
Live data · 2026-06-30 00:37 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed YBGJ - Latest Insights

YBGJ
Jun 12, 2026, 4:00 PM EDT
Filing Type: DEF 14C
Importance Score:
7
Price at Filing: $0.0084
Real-time Price: $0.0071 info
Change: Low Volume info
Market Cap: $1.21M info
YBGJ
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.0084
Real-time Price: $0.0071 info
Change: Low Volume info
Market Cap: $1.21M info
YBGJ
May 15, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0084
Real-time Price: $0.0071 info
Change: Low Volume info
Market Cap: $1.21M info